| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director
3 companies
Davidson Michael H. is a Chief Executive Officer at NAMS, with reported holdings spanning 3 companies. Recent filings cover 5 purchases and 10 sales. Those positions are worth an estimated $18.0M at current prices.
Our model assigns Davidson Michael H. a middling insider score of 65/100, based on 6 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +14.6%.
Davidson Michael H.'s largest disclosed position is in NAMS as Chief Executive Officer, worth about $18.0M. The recent filings there lean toward selling, a net 753,840 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | NAMS Newamsterdam Pharma Company N.V. | Chief Executive Officer | Buy | 10,000 | $22.65 | $226,500.00 | +1.3% | - | - | |
| Mar 2, 2026 | NAMS Newamsterdam Pharma Company N.V. | Chief Executive Officer | Sale+OE | 443,707 | $33.25 | $14,753,257.75 | -71.8% | -3.2% | - | |
| Feb 26, 2026 | NAMS Newamsterdam Pharma Company N.V. | Chief Executive Officer | Sale+OE10b5-1 | 306,293 | $34.53 | $10,575,091.20 | -63.8% | +6.7% | - | |
| Jan 7, 2026 | NAMS Newamsterdam Pharma Co N.V. | Chief Executive Officer | Sell10b5-1 | 11,582 | $0.00 | - | -3.0% | -4.3% | - | |
| Mar 26, 2025 | NAMS Newamsterdam Pharma Co N.V. | Chief Executive Officer | Sale+OE | 12,258 | $0.00 | - | -3.0% | -18.4% | +38.5% | |
| Aug 20, 2024 | NAMS Newamsterdam Pharma Co N.V. | Chief Executive Officer | Buy | 5,000 | $16.27 | $81,350.00 | +2.4% | +51.9% | +49.8% | |
| Aug 8, 2024 | TENX Tenax Therapeutics, Inc. | Director | Buy | 2,500 | $0.00 | - | +656.2% | +11.4% | +42.8% | |
| Jun 20, 2024 | NAMS Newamsterdam Pharma Co N.V. | Chief Executive Officer | Buy | 5,000 | $17.26 | $86,308.50 | +2.5% | -7.4% | +4.2% | |
| Sep 9, 2020 | LSTA Lisata Therapeutics, Inc. | Director | Buy | 55,525 | $1.80 | $99,945.00 | +108.7% | - | - |